SCHEMBL3268968

SCHEMBL3268968

NC(=O)COC(=O)NCC1CCN(c2ccc3ccccc3n2)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACACB O00763 7/20 0.49
ACACA Q13085 7/20 0.49
KCNH2 Q12809 1/20 0.47
PDE10A Q9Y233 6/20 0.45
PDE2A O00408 2/20 0.45
PDE1B Q01064 2/20 0.45
PDE4D Q08499 2/20 0.45
KDM4E B2RXH2 2/20 0.44
CYP3A4 P08684 2/20 0.44
HSD17B10 Q99714 2/20 0.44
HRH3 Q9Y5N1 1/20 0.44
CKS1B P61024 1/20 0.43
SKP1 P63208 1/20 0.43
SKP2 Q13309 1/20 0.43
HTR3E A5X5Y0 1/20 0.43
USP2 O75604 1/20 0.43
HTR3B O95264 1/20 0.43
ALDH1A1 P00352 1/20 0.43
CYP1A2 P05177 1/20 0.43
ADRB1 P08588 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL240267 0.90 PDE10A (0.44) ACACBACACAKCNH2PDE10APDE2A
SCHEMBL3265601 0.88 ACACB (0.49) ACACBACACAKCNH2PDE10APDE2A
SCHEMBL3267178 0.87 CKS1B (0.52) ACACBACACAKCNH2CKS1BSKP1
SCHEMBL10202397 0.86 HRH3 (0.47) ACACBACACAKCNH2PDE10AHRH3
SCHEMBL3266881 0.82 BDKRB1 (0.43) ACACBACACAKCNH2CKS1BSKP1
SCHEMBL240063 0.82 CKS1B (0.48) ACACBACACAKCNH2CKS1BSKP1
SCHEMBL3266871 0.80 LMNA (0.53) PDE10ACYP3A4ALDH1A1CYP1A2HTT
SCHEMBL3265544 0.80 MEN1 (0.42) ACACBACACAKCNH2KDM4EHSD17B10
SCHEMBL3265598 0.80 CKS1B (0.46) CKS1BSKP1SKP2
SCHEMBL3266160 0.80 TP53 (0.50) HTR3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120004207-A1 THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL-AND PIPERIDINYL-ALKYL CARBAMATES SANOFI-AVENTIS (FR) 2012-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004207-A1 THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL-AND PIPERIDINYL-ALKYL CARBAMATES CLCN2, CLIC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 ACACB 1063/4885ACACA 1566/4885KCNH2 49/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.